
MaioRegen Chondro+ for the treatment of cartilage lesions

MaioRegen is a multi-layered matrix, manufactured through a patented process.
The product, composed by collagen and hydroxyapatite enriched with magnesium, mimics the chondral and osteochondral tissues, both in the chemical composition and in the micro- and nano-structure.
Cartilage layer
Calcified cartilage and sub-chondral bone layer
Spongy bone layer
A) The damaged tissue is removed to create ab suitable lodging to host the implant and guarantee an adequate blood flow from the subchondral bone
B) Maioregen fits perfectly into lesion site, restoring anatomic continuity
C) The biomimetic porous structure and the chimical composition favour cellular migration. The bone marrow-derived cells selectively adhere to the collagen fibres, colonizing the entire scaffold
D) Cells proliferate, differentiate and synthesize matrix according to scaffold layer composition. The progressive resorption of MaioRegen and the simultaneous cell mediated remodeling favour the complete regeneration of the tissue

. MaioRegen Prime (tri-layer) is indicated for the treatment of single/multiple osteochondral lesions with severely compromised bone, Outerbridge Grade IV. Lesions can be f traumatic, post-traumatic or degenerative origin, as well as caused by osteochondritis dissecans (OCD).
. MaioRegen Slim (bi-layer) is indicated for the treatment of single/multiple osteochondral lesions with slightly compromised bone, Outerbridge Grade III and IV. Lesions can be f traumatic, post-traumatic or degenerative origin.
Both devices are also indicated for Early OA lesions, Grade I/II according to Kellgren&Lawrence, in absence of osteophytes and depending on the level of bone involvement.
. MaioRegen Chondro+ is indicated for the treatment of single/multiple chondral lesions, with no or slight alteration of the subchondral bone, Outerbridge Grade III and IV. Lesions can be f traumatic, post-traumatic or degenerative origin.

| Code | Description | |
|---|---|---|
| 01600401 | 2,0×3,0x0,2 cm | 1 |
| 01600400 | 3,0×4,0x0,2 cm | 1 |
| 01600403 | Ø = 1,2 cm H = 0,2 cm | 1 |
| 01600405 | Ø = 1,5 cm H = 0,2 cm | 1 |
| 01600404 | Ø = 1,8 cm H = 0,2 cm | 1 |


To date, more than 4.000 patients have been treated with MaioRegen, which is considered an effective and safe treatment.
A randomized controlled clinical trial (RCT) vs. microfracture (Level of Evidence 1) shows a statistical significant improvement in the clinical scores (IKDC Subjective, Tegner, KOOS, VAS) at 2 years follow-up.
MaioRegen has proven to be superior to microfracture in the following indications: deep osteochondral lesions, osteochondritis dissecans (OCD) and in the population of sport active patients.
Statistically significant superiority of MaioRegen vs. Microfracture (+12.4 points in change from baseline for IKDC subjective score).
Superiority of 12 points in change from baseline of MaioRegen vs. Microfracture in IKDC Subjective score.
Statistically significant superiority of MaioRegen vs. Microfracture (+16 points in change from baseline for IKDC subjective score).
Superiority of MaioRegen treatment in these populations provides clear indications for the treatment of osteochondral lesions with MaioRegen Prime.
Moreover, a pilot study with 27 patients shows the stability of clinical scores at 8 year of follow-up, in patients suffering from complex lesions treated with MaioRegen
Subjective IKDCX – 96 months follow-up
Tegner Score – 96 months follow-up

BLUE ELAF MEDICAL W.L.L.
Office 162, Floor 16,
Era58, Road No 1701,
Manama, Kingdom of Bahrain.
